Patrick J. Heron, Director at Arcutis Biotherapeutics, Inc. (ARQT), bought 21,052 shares at $9.50 ($200K) on 2024-03-04, disclosed to the SEC on 2024-03-06.
Open-market purchase of $200k ARQT by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| Filing → |
| ARQT | BUY | 2025-06-06 | $30K | — | Filing → |
| ARQT | BUY | 2025-05-23 | $69K | — | Filing → |
| ARQT | BUY | 2025-05-19 | $34K | — | Filing → |